ABOUT FACE BY NATURE
Phase 1- Indications
- Nasolabial folds, Lip volume enhancement, Fine lines around mouth
Company intelligence / Profile preview
The company’s lead program—a silk-based dermal filler using Activated Silk™ technology—has demonstrated a favorable safety profile in feasibility trials, with high patient satisfaction and clinically meaningful improvement in wrinkle severity. No device-related adverse events were reported; over 83% of patients had significant improvement at the primary endpoint. The pivotal trial for FDA approval began in early 2022. Products are not yet FDA approved as of latest available information. Pipeline breadth appears focused on this core product line.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Silk Medical Aesthetics.